Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Impact of Pilates Exercises Added to Pelvic Floor Muscle Training and Sildenafil on Diabetic Erectile Dysfunction. (PilatesDED2025)

13 novembre 2026 mis à jour par: Mahmoud Hamada Mohamed, Benha University

Pilates Exercises Added to Pelvic Floor Muscle Training and Sildenafil for Diabetic Erectile Dysfunction: A Randomized Controlled Trial

Erectile dysfunction (ED) has a prevalence of 52.5% in diabetic male patients, as described in a meta-analysis of 145 studies, including 88,577 men with type 1 and type 2 diabetes.

In men, ED can cause sexual dissatisfaction and distress, unsatisfactory relationships, and marital tension

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Description détaillée

Pilates emerged as a method of rehabilitation during World War I, when Joseph Hubertus Pilates applied his knowledge to rehabilitate injured men. The popularity of the method grew most in the 1980. More recently, Pilates has been used resulting in improved fitness (flexibility, strength and balance) and body consciousness. The method features ground-based exercises created by Joseph Pilates.

Because most Pilates exercises are performed in conjunction with the recruitment of PF muscle fibres, many Pilates instructors believe that the method can produce a significant increase in the force or contractility of the muscles. Furthermore, if Pilates promotes an improvement in the functioning of the pelvic floor muscles (PFM), it may be an alternative for the treatment and prevention of pelvic floor dysfunction.

Up till now, no published trials about impact of Pilate exercises on diabetic erectile dysfunction.

A total of 60 patients (n=30 per group), diagnosed with diabetic erectile dysfunction in the past 6 months. Participants will be recruited from Benha University hospital and local andrology and urology clinics in benha and giza . Participants will be screened for eligibility prior to being enrolled in the study participating in the study assessments.

Type d'étude

Interventionnel

Inscription (Réel)

60

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Benha
      • Banhā, Benha, Egypte
        • Outpatient clinic, faculty of Physical Therapy, Benha university

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

40 ans à 60 ans (Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Homme

La description

Inclusion Criteria:

  • Men aged 40-60 years.
  • Married.
  • Diagnosed with type 2 diabetes mellitus for >5 years, with initial diagnosis confirmed by HbA1c >6.5%.
  • Arteriogenic erectile dysfunction (ED) of >6 months' duration, diagnosed using the International Index of Erectile Function-5 (IIEF-5),confirmed by penile Doppler ultrasonography showing peak systolic velocity (PSV) of the cavernosal arteries <25 cm/s.
  • Body mass index (BMI) <30 kg/m².

Exclusion Criteria:

  • Poorly controlled diabetes mellitus (HbA1c >9%).
  • Neurogenic, venogenic, or psychogenic ED.
  • Cardiac conditions contraindicating sexual activity.
  • Neurological disorders or spinal cord injury.
  • Alcohol abuse or illicit drug use.
  • Chronic hematological disorders.
  • Active genitourinary infection.
  • Severe hypogonadism.
  • History of radical prostatectomy, pelvic surgery, or pelvic trauma.
  • Penile prosthesis implantation.
  • Current or previous participation in a structured pelvic floor muscle training or sexual rehabilitation program.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Expérimental

The program had 11 mat exercises: Pilates breathing, spine stretch, swan, shoulder bridge, hundreds, double leg stretch, footwork, roll up, single leg stretch, leg pull back, and kick front and back, It had three phases of four weeks each. In the beginner phase (weeks 1 to 4), participants did one set of six to eight repetitions of each exercise, using supported positions and modified movements to establish breathing coordination and lumbopelvic control. In the intermediate phase (weeks 5 to 8), they did two sets of eight to 10 repetitions with larger movement amplitude, longer lever arms, and more challenging limb movements. In the advanced phase (weeks 9 to 12), they did two sets of 10 to 12 repetitions of more complex variations with greater stabilization demands, provided they kept adequate movement control.

Participants attended an educational session conducted by a physiotherapist covering pelvic floor anatomy, the physiology of erection, and the roles of the ischiocavernosus and bulbocavernosus muscles in erectile function. They were instructed on proper pelvic floor muscle contraction using simulated interruption of urine flow and maximal voluntary contractions. A home-based PFMT program was prescribed, initially performed in the supine position with knees flexed and subsequently progressed to sitting or standing positions as tolerated. Participants were instructed to perform PFMT twice daily (morning and evening), consisting of 15 short contractions (1 second each) and 15 sustained contractions (6-10 seconds each). Adherence was monitored through a mobile messaging application, via which participants reported completion of their daily exercises and received reminders when necessary.

Participants received sildenafil citrate 25 mg orally once daily and sildenafil citrate 50 mg orally on demand, taken approximately 1 hour before sexual intercourse, throughout the study period.

Comparateur actif: Comparateur actif

Participants attended an educational session conducted by a physiotherapist covering pelvic floor anatomy, the physiology of erection, and the roles of the ischiocavernosus and bulbocavernosus muscles in erectile function. They were instructed on proper pelvic floor muscle contraction using simulated interruption of urine flow and maximal voluntary contractions. A home-based PFMT program was prescribed, initially performed in the supine position with knees flexed and subsequently progressed to sitting or standing positions as tolerated. Participants were instructed to perform PFMT twice daily (morning and evening), consisting of 15 short contractions (1 second each) and 15 sustained contractions (6-10 seconds each). Adherence was monitored through a mobile messaging application, via which participants reported completion of their daily exercises and received reminders when necessary.

Participants received sildenafil citrate 25 mg orally once daily and sildenafil citrate 50 mg orally on demand, taken approximately 1 hour before sexual intercourse, throughout the study period.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
International Index of Erectile Function-5 (IIEF-5) scale.
Délai: Baseline and after 12 weeks

The IIEF-5 scale is used to assess patients with erectile dysfunction to determine the extent of the erectile function in patients. The full-scale 15-item version has five domains: erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall sexual satisfaction.

The shortened 5-item version is on a scale of 5 to 25:

22-25: No erectile dysfunction 17-21: Mild erectile dysfunction 12-16: Mild to moderate erectile dysfunction 8-11: Moderate erectile dysfunction 5-7: Severe erectile dysfunction

Baseline and after 12 weeks

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
penile perfusion
Délai: Base line and after 12 weeks

Colour-coded duplex sonography (5-10 MHz probes) will be used for the evaluation of penile perfusion. Half ml of a vasoactive agent (trimix solution) will be injected into the corpus cavernosum. The systolic and diastolic velocities (cm/s) will be performed at 10 and 30 min for both cavernous artery. Re-dosing with 0.5 ml of trimax solution will be performed for patients who did not achieve adequate hardness. The highest values obtained will be recorded. The Doppler indices of the right and left cavernous arteries: peak systolic velocity (PSV)

Base line and after 12 weeks

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

15 décembre 2025

Achèvement primaire (Réel)

22 juin 2026

Achèvement de l'étude (Réel)

11 novembre 2026

Dates d'inscription aux études

Première soumission

8 décembre 2025

Première soumission répondant aux critères de contrôle qualité

8 décembre 2025

Première publication (Réel)

19 décembre 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 novembre 2026

Dernière vérification

1 décembre 2025

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • Pilate Exercises for DED2025

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .